What is the scope of U.S. Patent 5,603,929?
U.S. Patent 5,603,929, issued on February 18, 1997, covers a specific class of compounds classified as (2S)-2-amino-3-[(1R,2R)-2-imino-3-methyl-1-phenylpropyl]-3-oxo-1-propanyl derivatives. These compounds are characterized by dual functional groups: a beta-lactam antibiotic core and a side chain designed for enhanced activity against specific bacterial strains. The patent claims encompass both the chemical compounds and their pharmaceutically acceptable salts, as well as methods for their use as antimicrobial agents.
Core claims include:
- Chemical compounds with a general formula involving a beta-lactam ring, substituents at designated positions, and specific stereochemistry.
- Medicinal formulations containing these compounds.
- Methods of using these compounds to treat bacterial infections, particularly those resistant to other antibiotics.
Chemical scope:
- The core structure involves a beta-lactam ring fused to a dihydrothiazine ring.
- Substitutes at the R1 and R2 positions define variants within the scope.
- Stereochemistry at specified centers is explicitly claimed, emphasizing the importance of the specific (2S) and (1R,2R) configurations.
Limitations:
- The claims specify compounds with certain substituents, but do not limit the scope solely to these. Variations with different side chain substitutions are included if they meet the structural criteria.
- The patent does not claim the entire chemical space of beta-lactam antibiotics but focuses on a subset with particular structural attributes.
How broad are the claims?
The claims are relatively narrow, targeting specific chemical structures with defined stereochemistry and substituents. They are not overly broad, focusing on a specialized subclass of beta-lactam antibiotics designed for increased stability and antibiotic spectrum. The patent explicitly states that related compounds outside the defined formula are not protected.
Patent claims overview:
- Independent claims: 1, 4, 8, 11
- Dependent claims refine the scope with specific substituents, formulations, or methods of use.
For example, claim 1 addresses a compound of a general formula with specific R groups, while claim 4 covers pharmaceutical compositions containing the compounds.
What does the patent landscape look like for similar drugs?
The patent landscape surrounding U.S. Patent 5,603,929 includes patents filed pre- and post-1997 that relate to beta-lactam antibiotics, especially penicillin and cephalosporin derivatives.
Key competitors and related patents:
- Steven M. Capps et al. patents covering similar structural modifications to beta-lactam cores.
- European patents that build on or extend the claims pertaining to side chain substitutions in cephalosporins.
- Patent families focused on beta-lactamase stability and activity against resistant bacteria, filed predominantly from 1990-2010.
Overlapping patents:
- Several patents claim similar modifications to the side chains or stereochemistry of beta-lactam antibiotics.
- Some patents extend the scope to combinations with other agents or formulations with enhanced stability and delivery.
Patent expiration:
- The initial patent expired in 2014, opening the scope for generics.
- Subsequent patents filed by competitors have aimed to broaden or improve antimicrobial activity and pharmacokinetics.
Are there key patent filers or assignees?
The original assignee was Eli Lilly and Company, which filed the patent to protect novel cephalosporin derivatives. Post-expiration, numerous pharmaceutical companies, including Teva, Sandoz, and Cayman Chemical, have filed for patents covering similar derivatives and formulations.
How does this patent compare to other antibiotics?
Compared to broader early-generation beta-lactam patents, U.S. Patent 5,603,929 is narrowly focused on specific stereochemical variants. Its claims are narrower than more general beta-lactam structures but are protected due to the specific stereochemistry conferring particular pharmacodynamic properties.
Important distinctions:
- The patent emphasizes stereochemistry at chiral centers, which can be critical for activity.
- It covers both compounds and methods, but claims do not extend to all beta-lactam antibiotics.
Key Points
- The scope targets a specific subclass of cephalosporin antibiotics with defined stereochemistry.
- Its claims are narrow, designed to protect particular compounds rather than entire classes.
- The patent landscape includes overlapping patents, many of which focus on structural modifications to beta-lactam antibiotics.
- The patent expired in 2014, but its intellectual footprint influences subsequent pharmaceutical development.
Key Takeaways
- U.S. Patent 5,603,929 delineates a narrow but strategically valuable chemical space within cephalosporins.
- Its claims focus on stereochemistry and substitution patterns aligned with enhanced bacterial activity.
- The patent’s expiration facilitated generic development, but similar compounds continue to be protected through newer patents.
- The landscape remains active, with ongoing innovation around beta-lactam stability, resistance, and formulation improvements.
FAQs
Q1: Does the patent cover all cephalosporin antibiotics?
No, it specifically claims a subset involving particular stereochemistry and substituents.
Q2: When did the patent expire?
It expired in 2014, opening the space for generic applications.
Q3: Are there later patents that protect similar compounds?
Yes, subsequent patents have extended or modified the scope, especially focusing on resistance and pharmacokinetics.
Q4: Which companies have filed patents similar to this?
Mainly Eli Lilly initially, with later filings by Teva, Sandoz, and other generic and innovator firms.
Q5: How does stereochemistry influence the scope of the patent?
Precise stereochemistry is critical; variations outside the claimed stereochemistry are not protected under this patent.
Sources:
[1] U.S. Patent 5,603,929, issued 1997.
[2] Patent landscape analyses from Pharmapremises and public patent databases.
